Vanja Vaccaro

1.7k total citations · 1 hit paper
30 papers, 1.2k citations indexed

About

Vanja Vaccaro is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Vanja Vaccaro has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 13 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Vanja Vaccaro's work include Pancreatic and Hepatic Oncology Research (17 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Vanja Vaccaro is often cited by papers focused on Pancreatic and Hepatic Oncology Research (17 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Vanja Vaccaro collaborates with scholars based in Italy, Malaysia and United States. Vanja Vaccaro's co-authors include Michèle Milella, Francesco Cognetti, Ludovica Ciuffreda, Italia Falcone, Fabiana Conciatori, Emilio Bria, Federica Cuppone, Sabrina Vari, Ursula Cesta Incani and Anais Del Curatolo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Vanja Vaccaro

29 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

2015 375 citations Luisa Carbognin, Sara Pilotto et al. PLoS ONE profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vanja Vaccaro Italy	15	780	491	312	301	188	30	1.2k
Bradley G. Somer United States	16	808 1.0×	412 0.8×	304 1.0×	279 0.9×	123 0.7×	45	1.3k
Ramon Andrade de Mello Portugal	21	745 1.0×	477 1.0×	565 1.8×	314 1.0×	202 1.1×	89	1.4k
Jean‐Christophe Sabourin France	15	734 0.9×	492 1.0×	420 1.3×	243 0.8×	230 1.2×	29	1.4k
Thomas B. Karasic United States	16	711 0.9×	486 1.0×	279 0.9×	282 0.9×	111 0.6×	65	1.3k
Byung Woog Kang South Korea	19	508 0.7×	468 1.0×	198 0.6×	347 1.2×	130 0.7×	77	1.2k
Etienne Giroux‐Leprieur France	23	1.0k 1.3×	492 1.0×	706 2.3×	252 0.8×	194 1.0×	77	1.5k
Jia Luo United States	15	528 0.7×	328 0.7×	458 1.5×	288 1.0×	108 0.6×	64	1.0k
Takahiro Kogawa Japan	19	771 1.0×	334 0.7×	244 0.8×	338 1.1×	115 0.6×	86	1.2k
Hao‐Xiang Wu China	22	596 0.8×	520 1.1×	289 0.9×	393 1.3×	251 1.3×	38	1.3k
Jeremy Cetnar United States	14	905 1.2×	372 0.8×	788 2.5×	233 0.8×	171 0.9×	42	1.4k

Countries citing papers authored by Vanja Vaccaro

Since Specialization

Citations

This map shows the geographic impact of Vanja Vaccaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanja Vaccaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanja Vaccaro more than expected).

Fields of papers citing papers by Vanja Vaccaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanja Vaccaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanja Vaccaro. The network helps show where Vanja Vaccaro may publish in the future.

Co-authorship network of co-authors of Vanja Vaccaro

This figure shows the co-authorship network connecting the top 25 collaborators of Vanja Vaccaro. A scholar is included among the top collaborators of Vanja Vaccaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanja Vaccaro. Vanja Vaccaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferollà, Piero, Alfredo Berruti, Francesca Spada, et al.. (2022). Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. Neuroendocrinology. 113(3). 332–342. 16 indexed citations

Bazzichetto, Chiara, Claudio Luchini, Fabiana Conciatori, et al.. (2020). Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. International Journal of Molecular Sciences. 21(22). 8841–8841. 33 indexed citations

Bazzichetto, Chiara, Fabiana Conciatori, Claudio Luchini, et al.. (2020). From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer. Cells. 9(2). 309–309. 25 indexed citations

Giordano, Guido, Antonio Febbraro, Michèle Milella, et al.. (2016). Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. Journal of Clinical Oncology. 34(15_suppl). 4124–4124. 8 indexed citations

Carbognin, Luisa, Sara Pilotto, Michèle Milella, et al.. (2015). Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE. 10(6). e0130142–e0130142. 375 indexed citations breakdown →

Milella, Michèle, Italia Falcone, Fabiana Conciatori, et al.. (2015). PTEN: Multiple Functions in Human Malignant Tumors. Frontiers in Oncology. 5. 24–24. 358 indexed citations

Vaccaro, Vanja. (2015). Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. World Journal of Gastroenterology. 21(16). 4788–4788. 52 indexed citations

Ciuffreda, Ludovica, Italia Falcone, Ursula Cesta Incani, et al.. (2014). PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Advances in Biological Regulation. 56. 66–80. 75 indexed citations

Maftouh, Mina, Amir Avan, Niccola Funel, et al.. (2014). A Polymorphism in the promoter is Associated with EZH2 Expression but not with Outcome in Advanced Pancreatic Cancer Patients. Pharmacogenomics. 15(5). 609–618. 6 indexed citations

10.

Santoni, Matteo, Michele De Tursi, Alessandra Felici, et al.. (2013). Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Review of Anticancer Therapy. 13(6). 697–709. 13 indexed citations

11.

Avan, Amir, Paola Pacetti, Michele Reni, et al.. (2013). Prognostic factors in gemcitabine–cisplatin polychemotherapy regimens in pancreatic cancer: XPD‐Lys751Gln polymorphism strikes back. International Journal of Cancer. 133(4). 1016–1022. 23 indexed citations

12.

Vaccaro, Vanja. (2013). First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World Journal of Gastroenterology. 19(28). 4511–4511. 13 indexed citations

13.

Vaccaro, Vanja, Emilio Bria, Isabella Sperduti, et al.. (2012). Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice.. Journal of Clinical Oncology. 30(15_suppl). e14661–e14661. 2 indexed citations

14.

Loupakis, Fotios, Chiara Cremolini, Lisa Salvatore, et al.. (2011). Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer. Cancer. 118(6). 1523–1532. 29 indexed citations

15.

Vaccaro, Vanja, Davide Melisi, Emilio Bria, et al.. (2011). Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opinion on Therapeutic Targets. 15(10). 1183–1196. 44 indexed citations

16.

Cuppone, Federica, Emilio Bria, Vanja Vaccaro, et al.. (2011). Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. Journal of Experimental & Clinical Cancer Research. 30(1). 54–54. 27 indexed citations

17.

Bria, Emilio, Paolo Carlini, Federica Cuppone, et al.. (2010). Early recurrence risk: aromatase inhibitors versus tamoxifen. Expert Review of Anticancer Therapy. 10(8). 1239–1253. 5 indexed citations

18.

Cuppone, Federica, Emilio Bria, Diana Giannarelli, et al.. (2010). Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. BMC Cancer. 10(1). 675–675. 18 indexed citations

19.

Loupakis, Fotios, Emilio Bria, Vanja Vaccaro, et al.. (2010). Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Journal of Experimental & Clinical Cancer Research. 29(1). 58–58. 44 indexed citations

20.

Nisticò, Cecilia, Emilio Bria, Vanja Vaccaro, et al.. (2009). Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Anti-Cancer Drugs. 20(2). 109–114.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact